SPECGX LLC
PharmaSPECGX LLC is a pharmaceutical company focused on Immunology, Neurology, Metabolic.
SPECGX LLC's Key Drugs
SPECGX LLC's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, spanning Immunology and Neurology — its most strategically important drugs approved in the last 15 years.
SPECGX LLC's Recent FDA Approvals
New NDA/BLA approvals for SPECGX LLC over the last two years — novel drugs only, excluding generics and label supplements.
SPECGX LLC's Therapeutic Areas
SPECGX LLC's approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Neurology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SPECGX LLC's Top Competitors
SPECGX LLC's closest competitors by therapeutic-area and drug-target overlap include Eli Lilly, Roche, and Novo Nordisk. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SPECGX LLC Pipeline Snapshot
Active clinical trials for SPECGX LLC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1973-03-11
- Latest
- 2026-06-18
- Applications
- 65